On June 10, 2022 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported that data from multiple analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available (Press release, MorphoSys, JUN 10, 2022, View Source [SID1234615872]). The latest findings suggest pelabresib may have disease-modifying properties and confirm previous data supporting the potential of pelabresib as a treatment for patients with myelofibrosis. The data are being presented during oral and poster sessions at the European Hematology Association (EHA) (Free EHA Whitepaper) 2022 (EHA 2022) Hybrid Congress being held in Vienna.
"The standard for evaluating disease response in myelofibrosis focuses on symptom relief rather than true disease modification, which remains an unmet need for these patients," said John Mascarenhas, M.D., Director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, New York. "The body of data being presented at EHA (Free EHA Whitepaper) 2022 – including new findings that pelabresib may address cellular defects seen in myelofibrosis, thereby getting at the root cause of the disease – with correlated clinical improvements, suggests pelabresib may have the potential to enhance the current standard of care in the first-line treatment of myelofibrosis."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A study that will be presented in an oral session on June 11 analyzed cells derived from blood of patients who enrolled in the MANIFEST trial and from healthy volunteers. The findings indicate that pelabresib alone or in combination with the JAK inhibitor ruxolitinib may have the potential to improve the typical imbalance in the two white blood cell populations, the myeloid and lymphoid cells, and help restore normal blood cell development. These improvements also correlated with decreases in spleen volume, a key clinical measure of treatment success. Additionally, pelabresib alone or in combination decreased pro-inflammatory and pro-fibrotic signaling in monocytes, suggesting a potential attenuation of disease processes.
Page 1 of 4

"The latest findings from the MANIFEST trial at EHA (Free EHA Whitepaper) 2022 highlight the potential of pelabresib to offer patients and their physicians benefits over monotherapy with JAK inhibitors, if approved," said Malte Peters, M.D., MorphoSys Chief Research and Development Officer. "The full complement of MANIFEST data being presented this week suggests pelabresib may help improve outcomes for patients with myelofibrosis and reaffirms our confidence in the Phase 3 MANIFEST-2 study. We are committed to these patients, who need better options in first-line treatment and beyond."
A second oral presentation on June 11 highlights positive interim data from the MANIFEST trial on the safety and efficacy of pelabresib in combination with ruxolitinib in patients who were not previously treated with a JAK inhibitor and in those with suboptimal response to ruxolitinib. The findings show that the combination was generally well tolerated and offered reductions in spleen volume and symptom burden, with disease-modifying activity as measured by reduced levels of pro-inflammatory cytokines and improved bone marrow morphology. Over two-thirds (68%; n=57) of JAK inhibitor-naïve patients treated with the combination achieved at least a 35% reduction in spleen volume (SVR35) from baseline at week 24. Notably, 80% of patients achieved SVR35 at any time on study. Most patients also saw their symptoms reduced, with 56% (n=46) achieving at least a 50% reduction in total symptom score (TSS50) from baseline at week 24. No new safety signals were identified in the study. The most common hematologic adverse events were thrombocytopenia (12%, grade 3/4) and anemia (34%, grade 3/4). Non-hematological events included dyspnea (5%, grade 3) and respiratory tract infections (8%, grade 3/4).
In a poster presentation at EHA (Free EHA Whitepaper) 2022, matching-adjusted indirect comparisons were used to compare findings for the combination of pelabresib plus ruxolitinib in treatment-naïve patients with intermediate- or high-risk disease in one arm of the MANIFEST trial with findings from historical clinical trials examining the use of JAK inhibitor monotherapy in myelofibrosis. Adjusting for cross-trial differences, the estimated response rate ratios favored the pelabresib combination over ruxolitinib, fedratinib or momelotinib monotherapy for SVR35 and for TSS50, suggesting improved efficacy versus the JAK inhibitors alone.
A second poster presentation includes trial design information for the Phase 3 MANIFEST-2 study. MANIFEST-2, which is currently enrolling, will compare pelabresib in combination with ruxolitinib versus placebo plus ruxolitinib in approximately 400 patients with myelofibrosis who are naïve to JAK inhibitor therapy. MorphoSys is expected to report topline data from the MANIFEST-2 trial in the first half of 2024.
About Pelabresib
Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been evaluated or approved by any regulatory authorities.

About Myelofibrosis
Myelofibrosis is a type of chronic leukemia that causes extensive scarring in the bone marrow, which disrupts the body’s normal production of healthy blood cells. The result is a reduction in red blood cells, which can cause weakness and fatigue, and in platelets, which increases the risk of bleeding due to deficient clotting. Myelofibrosis
Page 2 of 4

often causes an enlarged spleen. It is most often diagnosed in people older than 50 and can occur on its own (called primary myelofibrosis) or because of another bone marrow disorder.

About MANIFEST
MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.

The MANIFEST trial is evaluating pelabresib in combination with ruxolitinib in JAK-inhibitor-naïve myelofibrosis patients (Arm 3), with a primary endpoint of the proportion of patients with a ≥35% spleen volume reduction from baseline (SVR35) after 24 weeks of treatment. The trial is also evaluating pelabresib either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1) or as add-on therapy in combination with ruxolitinib in patients with a suboptimal response to ruxolitinib or myelofibrosis progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on transfusion-dependent (TD) status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a ≥35% spleen volume reduction from baseline after 24 weeks of treatment.

Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST trial sponsor.

About MANIFEST-2
MANIFEST-2 (NCT04603495) is a global, double-blind, randomized Phase 3 clinical trial with pelabresib in combination with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. The primary endpoint of the study is a 35% or greater reduction in spleen volume (SVR35) from baseline at 24 weeks. A key secondary endpoint of the study is a 50% or greater improvement in total symptom score (TSS50) from baseline at 24 weeks.

Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor.

On June 10, 2022 Massive Bio Co-Founder and Chief Medical Officer Dr. Arturo Loaiza-Bonilla, MD, MSEd, reported that it will be featured in the BIO International Convention, presented by Biotechnology Innovation Organization (BIO) (Press release, Massive Bio, JUN 10, 2022, View Source [SID1234615871]). The BIO International Convention is the world’s largest gathering of leaders in the biotechnology and life sciences industries, bringing together thousands of biotechnology and pharmaceutical executives.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This event takes place in-person at the San Diego Convention Center in San Diego, California from June 13th to June 16th. Keynote speakers of the convention include Venus Williams and Erin Andrews.

Dr. Bonilla is a speaker in the discussion titled "The Roles of AI and Big Data in Precision Healthcare: Perspectives from the Drug Development Pathway and the Patient Journey" and takes place on June 15th at 2:00 pm ET. During this conference, panelists will discuss the role of Big Data and AI at each stage of the drug development pathway as concurrently intertwined with the patient’s journey as part of the developing precision healthcare field.

BIO is committed to speaking up for the millions of families around the globe who depend upon our success. Their goal is to drive a revolution that aims to cure patients, protect our climate, and nourish humanity.

In addition to being a Co-Founder of Massive Bio, Dr. Bonilla is a renowned medical oncologist and has a distinguished clinical career in precision medicine oncology, immunotherapy, clinical trial design, digital health, and patient advocacy. Visit the event’s full agenda.

Register to attend the in-person event on BIO’s website. Tag @MassiveBio and use #BIO2022 to connect on Twitter and other social media websites during the BIO International Convention from June 13th to June 16th.

On June 10, 2022 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, reported that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and an oral discussion session at the European Hematology Association (EHA) (Free EHA Whitepaper) 2022 Hybrid Congress (Press release, Kyowa Hakko Kirin, JUN 10, 2022, View Source [SID1234615870]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While many patients with indolent non-Hodgkin’s lymphomas, such as follicular lymphoma, achieve durable responses with current standard of care therapies, patients generally continue to need multiple treatments throughout the course of their disease due to relapse, necessitating the development of novel treatment options," stated Professor Wojciech Jurczak, M.D., Ph.D. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology in Kraków, Poland, presenter of the Phase 2 TIDAL study oral presentation and the Phase 3 COASTAL study principal investigator. "I believe the data presented at EHA (Free EHA Whitepaper) this year are very exciting and supportive of the zandelisib development program, particularly as we continue to enroll the Phase 3 COASTAL study evaluating zandelisib in combination with rituximab."

Clinical Data from the Phase 2 TIDAL Study Evaluating Zandelisib in Patients with Relapsed or Refractory Follicular Lymphoma

Study Details The ongoing TIDAL study (NCT03768505) is a global, open-label Phase 2 trial evaluating zandelisib as a single agent in two disease cohorts: one in relapsed or refractory (r/r) follicular lymphoma (FL) and one for r/r marginal zone lymphoma (MZL), in both cases after failure of at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody. Patients were administered zandelisib once daily for two 28-day cycles as response induction regimen, followed thereafter by once daily dosing for the first seven days of each subsequent 28-day cycle, an intermittent dosing (ID) regimen. The ID regimen was introduced to potentially allow Treg repopulation and to mitigate immune-mediated adverse events of special interest (AESI) without loss of disease control.

Enrollment in the FL cohort is complete; enrollment in the MZL cohort is ongoing. The FL cohort enrolled a total of 121 patients, with the first 91 consisting of the primary efficacy population (PEP) for the evaluation of overall response rate (ORR) and duration of response (DOR).

The median age of patients enrolled with FL was 64 years old. Enrolled patients were generally heavily pretreated; the median number of prior therapies was 3 (range 2-8) and 96% of patients had received prior chemoimmunotherapy. Further, 28 patients (23%) received prior stem cell transplant, 50 patients (41%) were refractory to last therapy, 41 patients (34%) had tumors ≥5 cm, and 68 patients (56%) were POD24 (progression of disease within 24 months of prior chemoimmunotherapy).

The primary efficacy endpoint is ORR as assessed by independent review committee (IRC) using a modified Lugano criteria. The data cutoff date is September 30, 2021, approximately 6 months after the last patient in the primary efficacy population (PEP) received their first dose of zandelisib. Data from the enrolling MZL cohort is not reported.

Efficacy The primary endpoint of ORR of zandelisib as a single agent in the PEP was 70.3% (N=64) as assessed by IRC; the complete response rate was 35.2% (N=32). Responses across sub-groups at high risk were all >63%:
• Refractory to last treatment: 64.3%
• >2 prior therapies: 63.3%
• POD24 (progression of disease within 24 months): 66.7% The ORR represents the primary endpoint of the TIDAL study. Responses were first observed in the first two cycles of therapy in 87.5% of all response (N=56), and 75% of all CRs (N=24) were observed in the first four cycles.

The disease control rate (CR+PR+SD) was 85%. As of the data cutoff date, the data are not sufficiently mature to accurately estimate the final DOR in the PEP. An additional data cut is planned for approximately 14 months after the last patient in the PEP is enrolled to evaluate DOR and provide more mature safety results. Best Change in SPD from Baseline* *7 patients not included because they did not have post-baseline imaging scans. (CR, complete response; MCR, metabolic complete response; SPD, sum of the product of the longest perpendicular diameters).

Safety and Tolerability With a median follow-up of 9.4 months (range 0.8-24) in the safety population of 121 pts, 9.9% (N=12) of patients had discontinued zandelisib due to any drug-related adverse event. Adverse events occurring in ≥ 10% of 121 patients regardless of relationship to zandelisib were: diarrhea, neutropenia, nausea, fatigue, abdominal pain, pyrexia, decreased appetite, constipation, rash and anemia.

Most Common Adverse Events Regardless of Relationship to Study Drug Grade 3 (AESI were diarrhea in 5% (N=6), colitis in 1.7% (N=2), cutaneous rash in 3.3% (N=4), stomatitis in 2.5% (N=3), and 0.8% (N=1) each for AST and ALT elevation, and non-infectious pneumonitis Primarily, Grade 3 AESIs to Date Occurred in Cycles 1-3. No Grade 4 or Grade 5 AESI were recorded. Cumulative Incidence of Time to First Occurrence of Grade 3 AESI Treatment-emergent COVID-19 infections (any grade) were reported in 8.3% (N=10) of patients, and 8.3% (N=10) of patients reported Grade 3 infections. Four COVID infections were fatal, as were 1 case each of pneumonia and tumor lysis syndrome.

Updated Clinical Data from the Phase 1B Study Evaluating Zandelisib in Patients with Relapsed or Refractory Follicular Lymphoma Poster Title: Zandelisib on Intermittent Dosing as a Single Agent or in Combination with Rituximab or Zanubrutinib in Relapsed or Refractory (r/r) Follicular Lymphoma (FL): Results from a Multi-Arm Phase 1b Study Session Title: Indolent & mantle cell non-Hodgkin lymphoma – Clinical Time: June 10, 2:30pm-3:45pm CEST Presenter: Jacob Drobnyk Soumerai, MD Abstract Code: P1114 Study Details The ongoing Phase 1B trial (NCT02914938) is an open-label, multi-arm, study evaluating zandelisib alone, in combination with rituximab or with zanubrutinib in about 160 patients with R/R chronic lymphocytic leukemia (CLL) or small Lymphocytic Lymphoma (SLL) or B-cell lymphoma. The presentation reports on the 69 patients enrolled with relapsed or refractory (r/r) follicular lymphoma (FL) across three groups: ‒ Group 1: Zandelisib single agent 60 mg once daily for two 28-day cycles then on the intermittent dosing (ID) schedule of 60 mg once daily on days 1-7 in cycles ≥3 ‒ Group 2: Zandelisib (same schedule as Group 1) in combination with rituximab 375 mg/m2 weekly x 4 in cycle 1 and on Day 1 of cycles 3-6 ‒ Group 3: Zandelisib 60 mg on ID from cycle 1 and zanubrutinib 80 mg twice daily Zandelisib administration was continued until disease progression or intolerance. Patients received a median of 2 prior therapies and 65% were POD24.

Safety and Tolerability With a median duration of drug exposure of 17.1 months in Group 1, 20.5 months in Group 2, and 7.1 months in Group 3, six patients (8.7%) discontinued therapy due to treatment related adverse events. Grade 3 AESI, ranging from 0% to 11% across all groups, were: diarrhea/colitis, AST/ALT increase, rash, infection and atrial fibrillation (with zanubrutinib only). No grade 4-5 adverse events of special interest were reported. One patient in Group 3 had reversible grade 4 drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Grade 3-4 neutropenia was observed in 11 pts (16%). Grade 3 AESIs by Treatment Group Excluding COVID-19, 7 patients (10.1%) had a grade 3 infection (2 had appendicitis, and 1 each had infectious diarrhea, CMV colitis, pneumonia, soft tissue infection, and tooth infection). COVID-19 was reported in 4 patients, fatal in 2: one with zandelisib alone and 1 with zandelisibrituximab. No other Grade 5 events were reported. Efficacy The overall response rate in the 65 evaluable patients was 84.6% (55/65) and the complete response rate was 24.6% (16/65). The overall response rate was 77.8% (14/18) in Group 1, 94.7% (18/19) in Group 2, and 82.1% (23/28) in Group 3. Response Rates The median duration of response in the heterogeneous patient groups with small patient populations was: 31.1 months in Group 1, 25.8 months in Group 2, and not yet mature in Group 3. The median drug exposure of 17.1, 20.5, and 7.1 months, respectively. Data cutoff: 10 Jan 2022.

Kaplan-Meier Estimate of Duration of Response "The data reported at the 2022 European Hematology Association (EHA) (Free EHA Whitepaper) demonstrate the potential of zandelisib, an investigation clinical candidate employing a unique intermittent dosing schedule, to provide a high response rate in a well-tolerated manner either as a single-agent or in combination with other therapies," said Richard Ghalie, M.D., chief medical officer of MEI Pharma. "We remain encouraged by zandelisib’s potential as we continue its development using the intermittent schedule as an oral, chemotherapy-free, time-limited, therapeutic option to meet the needs of patients." "The data presented at the EHA (Free EHA Whitepaper) congress support zandelisib’s potential value as a single agent or combination therapy," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin. "We continue to work with MEI Pharma to conduct global clinical trials with the goal of providing innovative treatment options for patients with B-cell malignancies." About Zandelisib Zandelisib, a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, potential therapeutic option for patients with B-cell malignancies. Clinical trials are investigating the efficacy and safety of zandelisib as a single agent and in combination with other modalities while administered on an Intermittent Dosing Regimen (ID) and in a timelimited manner when dosed in combination.

The ID leverages molecular and biologic properties specific to zandelisib. In November 2021, MEI Pharma and Kyowa Kirin announced data from ongoing Phase 2 TIDAL study (NCT03768505) evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies. Zandelisib demonstrated a 70.3% objective response rate (ORR) as determined by an Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. At the time of the data cutoff, the data were insufficiently mature to accurately estimate duration of response (DOR). In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months (range: 0.8-24) median duration of follow-up in the total study population (n=121), interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%. Patients enrolled in the study will continue to be followed for safety and DOR. Ongoing zandelisib studies include the cohort in TIDAL evaluating patients with r/r marginal zone lymphoma (MZL) and continuing evaluation of the cohort of patients in the study with r/r FL.

Also ongoing is the Phase 3 COASTAL study (NCT04745832), comparing zandelisib plus rituximab to standard of care chemotherapy plus rituximab in patients with r/r FL or MZL who received more than one prior line of therapy, which must have included an anti-CD20 antibody in combination with chemotherapy or lenalidomide. COASTAL, which is also evaluating timelimited intermittent administration of zandelisib, is intended to support marketing applications in the U.S. and globally. Other ongoing studies include a Phase 2 pivotal study in Japan (NCT04533581) in patients with indolent B-cell non-Hodgkin’s lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström’s macroglobulinemia (WM) conducted by Kyowa Kirin. In March 2020, the FDA granted zandelisib Fast Track designation for the treatment of adult patients with r/r follicular lymphoma who have received at least two prior systemic therapies. In November 2021, the FDA granted zandelisib Orphan Drug designation for the treatment of patients with follicular lymphoma.

In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib. MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S. About Follicular Lymphoma Follicular lymphoma (FL) is the most common indolent lymphoma, comprising about 20-30% of all non-Hodgkin lymphomas (NHL). The disease also forms on B cells, is chronic in most cases and tends to progress slowly. Most people diagnosed with FL are over 65 years of age. � Sometimes follicular lymphomas can transform into a more aggressive form of large B-cell lymphoma, a fast-growing (aggressive) type of NHL.

On June 10, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that President and CEO Robert E. Hoffman will present a corporate overview at the JMP Securities Life Sciences Conference (Press release, Kintara Therapeutics, JUN 10, 2022, View Source [SID1234615868]). The conference is being held on June 15 – 16, 2022 at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation at the JMP Securities Life Sciences Conference will be available on View Source A replay of the webcast will be available for 30 days after the date of the presentation.

Mr. Hoffman will be available for one-on-one meetings with registered attendees of the conference.

On June 10, 2022 Fusion Antibodies reported that it is delighted to be attending the 10th Antibody Industrial Symposium 2022 (AIS2022) (Press release, Fusion Antibodies, JUN 10, 2022, View Source [SID1234615867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AIS2022 will be held from 28th to 29th June 2022 in person in Montpellier, France. The AIS2022 is the ideal conference for scientists, industrials, physicians and policy makers to exchange about therapeutic antibodies and more!

Get in touch or log on to the event portal to organise a meeting with Aleksandra Bolbukova and Ryan Tough from the Fusion Antibodies team.